Carlos Fernandez

发表

Pearl's PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003

Greg Tardie, P. DePetrillo, C. Reisner, 2014 .

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil

M. Corboz, Zhili Li, D. Cipolla, 2020, ERJ Open Research.

A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.

Greg Tardie, D. Quinn, C. Reisner, 2014, Respiratory medicine.

Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease

S. Rennard, Greg Tardie, C. Fogarty, 2014, BMC Pulmonary Medicine.

Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development

K. Rabe, C. Reisner, C. Kollar, 2013 .

Pooled Analyses of Phase IIb Studies Support Dose Selection of Glycopyrrolate-Formoterol Fumarate (GFF) MDI (PT003) 18/9.6 μg for Phase III Development

K. Rabe, C. Reisner, C. Kollar, 2013 .

Pearl Therapeutics’ Combination LAMA/LABA MDI (GFF MDI, PT003) Provides Comparable Metabolic And ECG Safety To Spiriva® Handihaler® And Placebo In Patients With COPD

C. Reisner, C. Kollar, Carlos Fernandez, 2012, ATS 2012.

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis

J. Chalmers, Jun Zou, H. Usansky, 2022, Clinical Pharmacokinetics.

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis

J. Chalmers, Jun Zou, H. Usansky, 2022, Clinical Pharmacokinetics.

Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.

A. O'donnell, C. Daley, F. Blasi, 2020, The New England journal of medicine.

Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial

B. Korkmaz, J. Chalmers, D. Lasala, 2023, Respiratory Research.

Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults

Jun Zou, H. Usansky, A. Teper, 2022, Clinical pharmacology in drug development.